Temporary Policy on Repackaging or Combining Propofol Drug Products During the COVID-19 Public Health Emergency; Withdrawal of Guidance
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Food and Drug Administration (FDA or Agency) is announcing the withdrawal of the guidance for industry entitled "Temporary Policy on Repackaging or Combining Propofol Drug Products During the COVID-19 Public Health Emergency," which was issued in April 2020 to communicate a temporary policy regarding the repackaging or combining of propofol drug products. FDA is withdrawing this guidance document because the conditions that created the need for this policy described in the document have evolved and the policy is no longer needed.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.